cas 765-85-5|| where to buy Methyl cyclobutanecarboxylate

Nombre del producto:Methyl cyclobutanecarboxylate

IUPAC Name:methyl cyclobutanecarboxylate

Unidad de embalaje	Stock disponible	Precio($)
CM344654-10g	in stock	ǆǠ
CM344654-25g	in stock	ƩȋƏ

Sólo para uso en I+D..

Formulario de consulta

Nombre químico

Número CAS

Cantidad*

Especificaciones requeridas*
(% de ensayo, grado de material, etc.)

Nombre de contacto*

Correo electrónico de contacto*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 765-85-5 regularly via the above email.

Notas adicionales

Verification code*

refresh

: Núm. De CAS :765-85-5; Fórmula molecular:C6H10O2; Punto de fusión:-; Código de sonrisas:O=C(C1CCC1)OC; Densidad:

: Número de catálogo:CM344654; Peso molecular:114.14; Punto de ebullición:; Nº Mdl:MFCD00095142; Almacenamiento:

: Cyclobutanes; The molecular structure of cyclobutane has four carbon atoms, and its four carbon atoms are not in the same plane, which is the folded conformation of cyclobutane. Cyclobutane itself is not of commercial or biological interest, but more complex derivatives are important in biology and biotechnology. Currently, nine FDA-approved drugs contain the cyclobutane structure. From the perspective of therapeutic areas, cyclobutyl drugs are mainly distributed in popular areas such as tumors, neurological diseases, infectious diseases, endocrine and metabolic diseases.

: XRD-0394; XRad Therapeutics announced that the first patient has been dosed in the company’s Phase 1a trial evaluating XRD-0394 in combination with radiation therapy for the treatment of metastatic, locally-advanced or recurrent solid tumors.
XRD-0394, is a first-in-class dual inhibitor of ataxia-telangiectasia mutated (ATM) and DNA-dependent protein kinase (DNA-PK). Initial development efforts are focused on evaluating XRD-0394’s ability to enhance radiation therapy when used in combination. In parallel, the company is exploring the potential benefits of using XRad’s dual kinase inhibitors in combination with targeted radionuclides, immune checkpoint inhibitors, polyadenosine diphosphate-ribose polymerase inhibitors and antibody drug conjugates.